Biotech · Private company · Cleveland, OH, US
Haima Therapeutics, LLC
Track this companyFree. Adds Haima Therapeutics, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards7
- Commercialization Strategy for an Intravenous Hemostatic Nanotechnology for Bleeding ManagementFiscal year 2026 · $500KNIH RePORTER 1SB1HL184353-01 · fetched Nov 12, 2026
- A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet AgentsFiscal year 2026 · $50KNIH RePORTER 3R44HL180258-02S1 · fetched Nov 12, 2026
- A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet AgentsFiscal year 2026 · $978.2KNIH RePORTER 5R44HL180258-02 · fetched Nov 12, 2026
- A Novel Platelet-Inspired Nanotechnology to Restore Hemostasis in Patients on Antiplatelet AgentsFiscal year 2025 · $944.7KNIH RePORTER 1R44HL180258-01 · fetched Nov 12, 2026
- SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in ThrombocytopeniaFiscal year 2025 · $50KNIH RePORTER 3R44HL145948-03S2 · fetched Nov 12, 2026
- SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in ThrombocytopeniaFiscal year 2024 · $112.8KNIH RePORTER 3R44HL145948-03S1 · fetched Nov 12, 2026
- SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in ThrombocytopeniaFiscal year 2024 · $972.2KNIH RePORTER 5R44HL145948-03 · fetched Nov 12, 2026